Sg3 Management, LLC Protagonist Therapeutics, Inc Call Options Transaction History

Sg3 Management, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $52,950 - $191,400	7,500 Added 6.22%	128,000 $1.01 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $1.7 Million - $2.63 Million	73,000 Added 153.68%	120,500 $2.85 Million
Q4 2021 Feb 15, 2022	BUY	$17.63 - $37.1 $308,525 - $649,250	17,500 Added 58.33%	47,500 $1.63 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $388,500 - $1.49 Million	30,000 New	30,000 $532,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.